PubMed Health⌕ Search

PubMed · 11261526

Olanzapine-lnduced hyperglycemic nonketonic coma.

Abstract

OBJECTIVE: To report a case of olanzapine-induced hyperglycemia leading to a hyperosmolar, hyperglycemic, nonketonic coma. CASE SUMMARY: A 51-year-old, 85.5-kg (ideal body weight 79.9 kg), white man presented to a Veterans Affairs hospital with a serum glucose concentration of 1596 mg/dL. Soon thereafter, he went into a hyperosmolar, hyperglycemic, nonketonic coma. Olanzapine therapy had been instituted less than six months prior to this event; approximately two months before this event, his blood glucose was 108 mg/dL. Eight days after stopping olanzapine, the glucose concentration returned to normal, and the patient no longer required insulin nor any other glucose-lowering agents. DISCUSSION: The insulin resistance caused by olanzapine is normally attributed to the weight gain associated with the drug. In this patient, it appears that olanzapine caused hyperglycemia by a mechanism other than weight gain. CONCLUSIONS: This case report and others from the literature suggest that olanzapine therapy may induce hyperglycemia in some patients.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Roefaro, S M Mukherjee. 2001. Olanzapine-lnduced hyperglycemic nonketonic coma.. https://doi.org/10.1345/aph.10178

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Differential pharmacology of atypical antipsychotics: clinical implications.

PURPOSE: Pharmacology of atypical antipsychotics and the clinical implications are reviewed. SUMMARY: Psychiatric disorders, such as schizophrenia and bipolar disorder, are often associated with poor outcomes. Atypical antipsychotics have become the standard of care for these disorders, and multiple agents have demonstrated efficacy for both acute and maintenance therapy. As a result of their differential pharmacologic properties, atypical antipsychotics have diverse clinical profiles, resulting in different liabilities for specific adverse events. These effects can, in turn, have an adverse impact on patient functionality, adherence to therapy, and overall health. CONCLUSION: Atypical antipsychotics have distinct pharmacological profiles which result in clinically meaningful differences in adverse effects. Clinicians should have a wide choice of agents available with which to optimize outcomes in the majority of patients with psychiatric disorders.

Antipsychotic Agents↗